Is Novavax, Inc. (NVAX) a good stock to buy now?

Novavax, Inc. (NASDAQ: NVAX) is -16.04% lower on its value in year-to-date trading and has touched a low of $3.53 and a high of $11.36 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NVAX stock was last observed hovering at around $3.79 in the last trading session, with the day’s gains setting it 0.24%.

Currently trading at $4.03, the stock is -1.62% and -15.87% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 8.23 million and changing 6.33% at the moment leaves the stock -40.96% off its SMA200. NVAX registered -61.40% loss for a year compared to 6-month loss of -47.59%. The firm has a 50-day simple moving average (SMA 50) of $0.05 and a 200-day simple moving average (SMA200) of -$0.10.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The stock witnessed a -16.74% gain in the last 1 month and extending the period to 3 months gives it a -40.74%, and is 2.54% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.42% over the week and 5.53% over the month.

Profit margin for the company is -52.29%. Distance from 52-week low is 14.09% and -64.52% from its 52-week high.

Novavax, Inc. quarterly earnings per share for the current quarter are estimated at -$0.5 with sales reaching $321.65M over the same period.The EPS is expected to grow by 49.98% this year, but quarterly earnings will post -48.80% year-over-year. Quarterly sales are estimated to shrink -10.00% in year-over-year returns.

Novavax, Inc. (NVAX) Top Institutional Holders

300 institutions hold shares in Novavax, Inc. (NVAX), with institutional investors hold 63.61% of the company’s shares. The shares outstanding are 118.79M, and float is at 111.93M with Short Float at 46.54%. Institutions hold 59.91% of the Float.

The top institutional shareholder in the company is State Street Corporation with over 11.68 million shares valued at $86.78 million. The investor’s holdings represent 12.37% of the NVAX Shares outstanding. As of Jun 29, 2023, the second largest holder is Vanguard Group Inc with 10.57 million shares valued at $78.55 million to account for 11.20% of the shares outstanding. The other top investors are Blackrock Inc. which holds 6.99 million shares representing 7.41% and valued at over $51.97 million, while Shah Capital Management holds 6.71% of the shares totaling 6.33 million with a market value of $45.83 million.

Novavax, Inc. (NVAX) Insider Activity

A total of 9 insider transactions have happened at Novavax, Inc. (NVAX) in the last six months, with sales accounting for 4 and purchases happening 5 times. The most recent transaction is an insider purchase by Glenn Gregory M ,the company’sPresident, R&D. SEC filings show that Glenn Gregory M bought 1,000 shares of the company’s common stock on Mar 10 at a price of $6.50 per share for a total of $6500.0. Following the purchase, the insider now owns 14473.0 shares.

Novavax, Inc. disclosed in a document filed with the SEC on Mar 07 that Glenn Gregory M (President, R&D) bought a total of 2,000 shares of the company’s common stock. The trade occurred on Mar 07 and was made at $7.04 per share for $14088.0. Following the transaction, the insider now directly holds 13473.0 shares of the NVAX stock.

Still, SEC filings show that on Mar 06, Glenn Gregory M (President, R&D) acquired 3,000 shares at an average price of $7.48 for $22454.0. The insider now directly holds 11,473 shares of Novavax, Inc. (NVAX).

Novavax, Inc. (NVAX): Who are the competitors?

The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -3.68% down over the past 12 months. Pfizer Inc. (PFE) that is -37.35% lower over the same period.